Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the relative contributions of basal hyperglycemia (BHG) versus postprandial hyperglycemia (PPHG) before and after treatment intensification in patients with glycated hemoglobin A1c (A1C) >7.0% while on prior oral therapy. RESEARCH DESIGN AND METHODS: Self-measured, plasma-referenced glucose profiles and A1C values were evaluated from participants in six studies comparing systematically titrated insulin glargine with an alternative regimen (adding basal, premixed, or prandial insulin, or increasing oral agents). Hyperglycemic exposure (>100 mg/dL [5.6 mmol/L]) as a result of BHG versus PPHG was calculated. RESULTS: On prior oral therapy, 1,699 participants (mean age 59 years, diabetes duration 9 years) had mean fasting plasma glucose (FPG) of 194 mg/dL (10.8 mmol/L), and mean A1C was 8.7%. BHG contributed an average of 76–80% to hyperglycemia over the observed range of baseline A1C levels. Adding basal insulin for 24 or 28 weeks lowered mean FPG to 117 mg/dL (6.5 mmol/L), A1C to 7.0%, and BHG contribution to 32–41%. Alternative regimens reduced FPG to 146 mg/dL (8.1 mmol/L), A1C to 7.1%, and the contribution of BHG to 64–71%. BHG contributions for patients with A1C averaging 7.6–7.7% were 76% at baseline and 34 and 68% after adding basal insulin or other therapies, respectively. CONCLUSIONS: When A1C is >7.0% despite oral therapy, BHG routinely dominates exposure. Intensified therapy reduces A1C and changes this relationship, but BHG amenable to further intervention still accounts for one-third of total hyperglycemia after basal insulin treatment and two-thirds after alternative methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When A1C values are higher, the major contribution is the FPG levels, but as the A1C value approaches the target value of ≤7.0%, there is a greater contribution from PPG values (37-39).”
From Targets for Glycemic Control (2018) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 3×
“89) AUCB (mg z h z dL (21)) Baseline 2,155 (1,176) 2,271 (1,183) 1,821 (1,091) 2,598 (1,220) 2,449 (1,256)”
BackgroundInfluentialMonnier, L., Colette, C., Dunseath, G. J., & Owens, D. R. (2007) · Diabetes Care · doi:10.2337/dc06-1612 · Cited by 490
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
Self-citation
Cited by
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Diabetes Care · doi:10.2337/dc12-1609 · Cited by 335
Inter-organ cross-talk in metabolic syndrome
Priest, C., & Tontonoz, P. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0145-5 · Cited by 279
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Self-citationSeino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255
Riddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Self-citationReznik, Y., Cohen, O., Aronson, R., Conget, I., Runzis, S., Castaneda, J., & Lee, S. W. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61037-0 · Cited by 233
Kapitza, C., Forst, T., Coester, H. ‐., Poitiers, F., Ruus, P., & Hincelin‐Méry, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 191
Wright, L. A.-C., & Hirsch, I. B. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0029 · Cited by 178
Insulin Therapy for Type 2 Diabetes Mellitus
Wallia, A., & Molitch, M. E. (2014) · JAMA · doi:10.1001/jama.2014.5951 · Cited by 153
Glycemic variability: how to measure and its clinical implication for type 2 diabetes
Umpierrez, G. E., & P. Kovatchev, B. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.09.010 · Cited by 148
Self-citationDall'Alba, V., Silva, F. M., Antonio, J. P., Steemburgo, T., Royer, C. P., Almeida, J. C., Gross, J. L., & Azevedo, M. J. (2013) · British Journal of Nutrition · doi:10.1017/s0007114513001025 · Cited by 117
Kautzky‐Willer, A., Kosi, L., Lin, J., & Mihaljevic, R. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12449 · Cited by 112
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
“…(SMBG) using fingerstick testing is still recommended to help most people with T2DM to make Perspective decreasing as HbA 1c levels rise, such that in people with the highest HbA 1c levels (>10.2%), PPG contributes around 30% of the elevated glycaemic exposure, with PPG making up about 70% 35 .”
InfluentialImran, S. A., Agarwal, G., Bajaj, H. S., & Ross, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.030 · Cited by 113
Watson, L. E., Xie, C., Wang, X., Li, Z., Phillips, L. K., Sun, Z., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02736 · Cited by 99
Kothny, W., Foley, J. E., Kozlovski, P., Shao, Q., Gallwitz, B., & Lukashevich, V. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12020 · Cited by 100
Identifying and meeting the challenges of insulin therapy in type 2 diabetes
Sorli, C., & Heile, M. K. (2014) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s64084 · Cited by 88
Update on biomarkers of glycemic control
Krhač, M., & Lovrenčić, M. V. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i1.1 · Cited by 93
Whey protein: The “whey” forward for treatment of type 2 diabetes?
Mignone, L. E. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i14.1274 · Cited by 90
Home, P. D. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12501 · Cited by 90
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
Gerich, J. (2013) · International Journal of General Medicine · doi:10.2147/ijgm.s51665 · Cited by 77
Insulin Initiation and Titration in Patients With Type 2 Diabetes
Chun, J. H., Strong, J. L., & Urquhart, S. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0005 · Cited by 92
Heise, T., Zijlstra, E., Nosek, L., Rikte, T., & Haahr, H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12803 · Cited by 78
Owens, D., Monnier, L., & Bolli, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.004 · Cited by 82
Monnier, L., & Colette, C. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30003-9 · Cited by 78
Rapid gastric emptying in diabetes mellitus: Pathophysiology and clinical importance
Goyal, R. K., Cristofaro, V., & Sullivan, M. P. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107414 · Cited by 75
Jones, K. L., Rigda, R. S., Buttfield, M. D. M., Hatzinikolas, S., Pham, H. T., Marathe, C. S., Wu, T., Lange, K., Trahair, L. G., Rayner, C. K., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13633 · Cited by 66
Evidence for Central Regulation of Glucose Metabolism
Carey, M., Kehlenbrink, S., & Hawkins, M. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.506782 · Cited by 71
Tay, J., Thompson, C. H., & Brinkworth, G. D. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-121214-104422 · Cited by 61
Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
Hershon, K. S., Hirsch, B. R., & Odugbesan, O. (2019) · Clinical Diabetes · doi:10.2337/cd18-0040 · Cited by 67
de Carvalho, C. M., de Paula, T. P., Viana, L. V., Machado, V. M., de Almeida, J. C., & de Azevedo, M. J. (2017) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.157263 · Cited by 73
Melo, K., Bahia, L., Pasinato, B. P. R., Porfírio, G. J. M., Martimbianco, A. L. C., Riera, R., Calliari, L. E., Minicucci, W. J., Turatti, L. A. A., Pedrosa, H. C., et al. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0397-3 · Cited by 67
Watson, L. E., Phillips, L. K., Wu, T., Bound, M. J., Checklin, H. L., Grivell, J., Jones, K. L., Clifton, P. M., Horowitz, M., & Rayner, C. K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13604 · Cited by 58
Sharma, D., Ojha, H., Pathak, M., Singh, B. M., Sharma, N., Singh, A., Kakkar, R., & Sharma, R. K. (2016) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2016.04.030 · Cited by 59
Benefits of timely basal insulin control in patients with type 2 diabetes
Lovre, D., & Fonseca, V. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.11.018 · Cited by 60
Lind, M., Tuomilehto, J., Uusitupa, M., Nerman, O., Eriksson, J., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Peltonen, M., Pivodic, A., & Lindström, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109506 · Cited by 53
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
Ahrén, B. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.40 · Cited by 51
Measurement of gastric emptying in diabetes
Phillips, L. K., Rayner, C. K., Jones, K. L., & Horowitz, M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.06.005 · Cited by 54
Rayner, C. K., Watson, L. E., Phillips, L. K., Lange, K., Bound, M. J., Grivell, J., Wu, T., Jones, K. L., Horowitz, M., Ferrannini, E., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0190 · Cited by 50
Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
Becker, R. H. A., Stechl, J., Steinstraesser, A., Golor, G., & Pellissier, F. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2647 · Cited by 49
Hinzmann, R., Schlaeger, C., & Tran, C. T. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.4520 · Cited by 62
Lukashevich, V., Schweizer, A., Foley, J. E., Dickinson, Groop, P., & Kothny, W. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s39300 · Cited by 55
Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
Charbonnel, B., Bertolini, M., Tinahones, F. J., Domingo, M. P., & Davies, M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.07.007 · Cited by 48
Rodbard, H. W., Cariou, B., Pieber, T. R., Endahl, L. A., Zacho, J., & Cooper, J. G. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12609 · Cited by 49
Owens, D. R. (2013) · Diabetic Medicine · doi:10.1111/dme.12019 · Cited by 49
How much is too much? Outcomes in patients using high‐dose insulin glargine
Reid, T., Gao, L., Gill, J., Stuhr, A., Traylor, L. B., Vlajnic, A., & Rhinehart, A. S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12747 · Cited by 48
Raccah, D., Chou, E., Colagiuri, S., Gaàl, Z., Lavalle, F., Mkrtumyan, A., Nikonova, E., Tentolouris, N., Vidal, J., & Davies, M. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2858 · Cited by 47
Basal Glucose Can Be Controlled, but the Prandial Problem Persists—It’s the Next Target!
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dc16-2380 · Cited by 39
Self-citationRosenstock, J., Franco, D., Korpachev, V., Shumel, B., Ma, Y., Baughman, R., Amin, N., McGill, J. B., & for the Affinity 2 Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0629 · Cited by 43
Self-citationVigersky, R. A., Huang, S., Cordero, T. L., Shin, J., Lee, S. W., Chhabra, H., Kaufman, F. R., & Cohen, O. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0234 · Cited by 43
Manipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners
Shibib, L., Al-Qaisi, M., Guess, N. D., Miras, A. D., Greenwald, S. E., Pelling, M., & Ahmed, A. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s458894 · Cited by 48
Jia, W., Xiao, X., Ji, Q., Ahn, K. J., Chuang, L., Bao, Y., Pang, C., Chen, L., Gao, F., Tu, Y., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00041-8 · Cited by 43
Hinnen, D. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.4.175 · Cited by 42
Wright, L. A.-C., & Hirsch, I. B. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.141 · Cited by 45
Insulin Therapy in Type 2 Diabetes Mellitus
Leahy, J. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.004 · Cited by 43
Munshi, M. N., Pandya, N., Umpierrez, G. E., DIGENIO, A. G., Zhou, R., & Riddle, M. C. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12167 · Cited by 44
Self-citationBlood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections
Li, F.-F., Fu, L., Zhang, W., Su, X., Wu, J.-D., Sun, J., Ye, L., & Ma, J. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1028945 · Cited by 41
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
“As stated above, after initiation of treatment with basal insulin, which decreases fasting glucose, the relative contribution of postprandial hyperglycemia to total hyperglycemia increases from 20–24% to 59–69% [4].”
BackgroundInfluentialPaing, A. C., McMillan, K. A., Kirk, A. F., Collier, A., Hewitt, A., & CHASTIN, S. F. M. (2018) · Diabetic Medicine · doi:10.1111/dme.13829 · Cited by 40
Hafiz, M. S., Campbell, M. D., O’Mahoney, L. L., Holmes, M., Orfila, C., & Boesch, C. (2022) · European Journal of Nutrition · doi:10.1007/s00394-021-02685-y · Cited by 38
Leahy, J. (. L., Aleppo, G., Fonseca, V. A., Garg, S. K., Hirsch, I. B., McCall, A. L., McGill, J. B., & Polonsky, W. H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00222 · Cited by 34
The role of insulin pump therapy for type 2 diabetes mellitus
Landau, Z., Raz, I., Wainstein, J., Bar‐Dayan, Y., & Cahn, A. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2822 · Cited by 38
Ma, J., Checklin, H. L., Wishart, J. M., Stevens, J. E., Jones, K. L., Horowitz, M., Meyer, J. H., & Rayner, C. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2876-2 · Cited by 36
Raccah, D., Lin, J., Wang, E., Germé, M., Perfetti, R., Bonadonna, R. C., de Pablos-Velasco, P. L., Roussel, R., & Rosenstock, J. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.10.003 · Cited by 33
Self-citationBlonde, L., Anderson, J. E., Chava, P., & Dendy, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541790 · Cited by 33
Spectroscopic and thermodynamic studies of the binding mechanism of metformin to pepsin
Pathak, M., Sharma, D., Sharma, N., & Sharma, M. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.04.032 · Cited by 32
Krzymień, J., & Ładyżyński, P. (2019) · Nutrients · doi:10.3390/nu11030607 · Cited by 42
Watson, L. E., Phillips, L. K., Wu, T., Bound, M. J., Checklin, H. L., Grivell, J., Jones, K. L., Horowitz, M., & Rayner, C. K. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.014 · Cited by 30
Kim, M. K., Jeong, J. S., Kwon, H., Baek, K. H., & Song, K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.04.015 · Cited by 28
Goldenberg, R., & Berard, L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1372118 · Cited by 27
Ma, J., Liu, L. Y., Wu, P., Liao, Y., Tao, T., & Liu, W. (2014) · Journal of Diabetes Research · doi:10.1155/2014/294017 · Cited by 27
Central KATP Channels Modulate Glucose Effectiveness in Humans and Rodents
Admin, A., Carey, M., Lontchi‐Yimagou, E., Mitchell, W., Reda, S., Zhang, K., Kehlenbrink, S., Koppaka, S., Maginley, S. R., Aleksić, S., et al. (2020) · Diabetes · doi:10.2337/db19-1256 · Cited by 26
Harris, S. B., Yale, J.-F., Berard, L., Stewart, J., Abbaszadeh, B., Webster-Bogaert, S., & Gerstein, H. C. (2014) · Diabetes Care · doi:10.2337/dc13-1636 · Cited by 19
Mata‐Cases, M., Mauricio, D., & Franch‐Nadal, J. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12373 · Cited by 28
Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2013) · BioDrugs · doi:10.1007/s40259-013-0057-y · Cited by 26
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 25
Self-citationZisman, A., Morales, F., Stewart, J. A., Stuhr, A., Vlajnic, A., & Zhou, R. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000171 · Cited by 25
Self-citationAronson, R., Cohen, O., Conget, I., Runzis, S., Castañeda, J., de Portu, S., Lee, S., Reznik, Y., & for the OpT2mise Study Group (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0363 · Cited by 26
Silva, A. M. N., Sousa, P. R. H., Coimbra, J. T. S., Brás, N. F., Vitorino, R. M. P., Fernandes, P. A., Ramos, M. J., Rangel, M., & Domingues, P. M. (2014) · Biochemical Journal · doi:10.1042/bj20140133 · Cited by 22
Inzucchi, S. E., Umpierrez, G. E., DIGENIO, A. G., Zhou, R., & Kovatchev, B. P. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.12.020 · Cited by 20
Self-citationGheldof, N., Francey, C., Rytz, A., Egli, L., Delodder, F., Bovetto, L., Piccardi, N., & Darimont, C. (2022) · Nutrients · doi:10.3390/nu14132674 · Cited by 21
Giorgino, F., Bonadonna, R., Gentile, S., Vettor, R., & Pozzilli, P. (2016) · Diabetes/Metabolism Research Reviews · doi:10.1002/dmrr.2775 · Cited by 17
Maahs, D. M., Chase, H. P., Westfall, E., Slover, R. H., Huang, S., Shin, J., KAUFMAN, F. R., Pyle, L. L., & Snell‐Bergeon, J. K. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0227 · Cited by 18
Kang, X., Wang, C., Chen, D., Lv, L., Liu, G., Xiao, J., Yang, Y., He, L., Chen, L., Li, X., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0327 · Cited by 19
Bonadonna, R. C., Blonde, L., Antsiferov, M. B., Berria, R., Gourdy, P., Hatunic, M., Mohan, V., & Horowitz, M. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2897 · Cited by 18
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes
Bolli, G. B., Home, P. D., Porcellati, F., Riddle, M. C., Gerstein, H. C., Lucidi, P., Fanelli, C. G., & Owens, D. R. (2025) · Diabetes Care · doi:10.2337/dci24-0104 · Cited by 19
Self-citationPeter, R., Dunseath, G. J., Luzio, S. D., & Owens, D. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.07.001 · Cited by 16
Raccah, D., Gourdy, P., Sagnard, L., & Ceriello, A. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2548 · Cited by 14
Scheen, A. J., Schmitt, H., Jiang, H. H., & Iványi, T. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.03.002 · Cited by 15
Lixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
Riddle, M. C., & Gerstein, H. C. (2015) · Diabetes Care · doi:10.2337/dc15-1073 · Cited by 15
Self-citationAlbèr, A., Brønden, A., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12911 · Cited by 14
Dalan, R., Earnest, A., & Leow, M. K. (2013) · Endocrine Practice · doi:10.4158/ep12417.or · Cited by 18
Yang, W., Xu, X., Liu, X.-M., Yang, G., Seino, Y., Andersen, H., & Jinnouchi, H. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.838155 · Cited by 14
The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin
Shaefer, C. F., & Anderson, J. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1103640 · Cited by 15
Raccah, D. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.11.007 · Cited by 15
Wojciechowski, P., Niemczyk-Szechowska, P., Olewińska, E., Jaros, P., Mierzejewska, B., Skarzynska-Duk, J., Malecki, M. T., & Rys, P. (2015) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.2705 · Cited by 18
Moon, J., Kim, J. Y., Yoo, S., & Koh, G. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.290 · Cited by 15
Vinagre, I., Sánchez-Hernández, J. J., Sánchez‐Quesada, J. L., María, M. A. M., de Leiva, A., & Pérez, A. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.11.009 · Cited by 13
Metadata
- Authors
- Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J.
- Affiliations
- Oregon Health & Science University (US)
- Emory University (US)
- Sanofi (United States) (US)
- Medpace (United States) (US)
- Dallas Diabetes and Endocrine Center, Dallas, Texas
- Corresponding author
- Riddle, Matthew
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-11-14
- Volume
- 34
- Issue
- 12
- Pages
- 2508-2514
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3220846
- OpenAlex
- W2103903409
- Cited by
- 219
- References
- 20
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 12 · 2020: 13 · 2019: 22 · 2018: 13 · 2017: 17 · 2016: 18 · 2015: 28 · 2014: 22 · 2013: 29 · 2012: 8
- FWCI
- 16.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Medpace
- MannKind Corporation
- European Foundation for the Study of Diabetes
- Novo Nordisk
- National Institutes of Health (UL1TR000454)
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, postprandial hyperglycemia, HbA1c, treatment intensification, insulin glargine, basal insulin, oral antidiabetic drugs, fasting blood glucose, glycemic control
- MeSH terms
- Isophane Insulin, Human, Insulin Glargine, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Insulin, Isophane, Male, Middle Aged, Randomized Controlled Trials as Topic, Treatment Outcome, Insulin, Long-Acting, Insulin, Regular, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.